Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Small-molecule dual PLK1 and BRD4 inhibitors are active against preclinical models of pediatric solid tumors

[img]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
2MB
[img] Other (Supplementary Data)
14MB

Item Type:Article
Title:Small-molecule dual PLK1 and BRD4 inhibitors are active against preclinical models of pediatric solid tumors
Creators Name:Timme, Natalie and Han, Youjia and Liu, Shuai and Yosief, Hailemichael O and García, Heathcliff Dorado and Bei, Yi and Klironomos, Filippos and MacArthur, Ian C and Szymansky, Annabell and von Stebut, Jennifer and Bardinet, Victor and Dohna, Constantin and Künkele, Annette and Rolff, Jana and Hundsdörfer, Patrick and Lissat, Andrej and Seifert, Georg and Eggert, Angelika and Schulte, Johannes H and Zhang, W. and Henssen, A.G.
Abstract:Simultaneous inhibition of multiple molecular targets is an established strategy to improve the continuance of clinical response to therapy. Here, we screened 49 molecules with dual nanomolar inhibitory activity against BRD4 and PLK1, best classified as dual kinase-bromodomain inhibitors, in pediatric tumor cell lines for their antitumor activity. We identified two candidate dual kinase-bromodomain inhibitors with strong and tumor-specific activity against neuroblastoma, medulloblastoma, and rhabdomyosarcoma tumor cells. Dual PLK1 and BRD4 inhibitor treatment suppressed proliferation and induced apoptosis in pediatric tumor cell lines at low nanomolar concentrations. This was associated with reduced MYCN-driven gene expression as assessed by RNA sequencing. Treatment of patient-derived xenografts with dual inhibitor UMB103 led to significant tumor regression. We demonstrate that concurrent inhibition of two central regulators of MYC protein family of protooncogenes, BRD4, and PLK1, with single small molecules has strong and specific antitumor effects in preclinical pediatric cancer models.
Source:Translational Oncology
ISSN:1936-5233
Publisher:Elsevier / Neoplasia Press
Volume:13
Number:2
Page Range:221-232
Date:February 2020
Official Publication:https://doi.org/10.1016/j.tranon.2019.09.013
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library